Evidence map›Paper›PMID 38109696›Full record

ArticleCardiovascular research2024

Sphingosine-1-phosphate receptor 3 regulates the transendothelial transport of high-density lipoproteins and low-density lipoproteins in opposite ways.

Srividya Velagapudi, Dongdong Wang, Francesco Poti, Renata Feuerborn, Jerome Robert, Eveline Schlumpf, Mustafa Yalcinkaya, Grigorios Panteloglou, Anton Potapenko, Manuela Simoni and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Srividya VelagapudiInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland.
Dongdong WangInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland.ORCID 0000-0002-6195-4428
Francesco PotiDepartment of Medicine and Surgery-Unit of Neurosciences, University of Parma, Parma, Italy.ORCID 0000-0002-1708-0719
Renata FeuerbornCentral Laboratory Facility, University Hospital of Münster, Münster, Germany.
Jerome RobertInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland.
Eveline SchlumpfInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland.
Mustafa YalcinkayaInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland.
Grigorios PanteloglouInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland.ORCID 0000-0002-7672-7623
Anton PotapenkoInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland.
Manuela SimoniDepartment of Biomedical, Metabolic and Neural Sciences-Unit of Endocrinology, University of Modena and Reggio Emilia, Modena, Italy.ORCID 0000-0002-2133-4304
Lucia RohrerInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland.
Jerzy-Roch NoferCentral Laboratory Facility, University Hospital of Münster, Münster, Germany.
Arnold von EckardsteinInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland.ORCID 0000-0002-1666-2266
University of Zurich · CHUniversity Hospital Münster · DEUniversity of Modena and Reggio Emilia · IT

Funding

Swiss National Science Foundation 31003A-160216
6 · The paper itself

Abstract

aimsThe entry of lipoproteins from blood into the arterial wall is a rate-limiting step in atherosclerosis. It is controversial whether this happens by filtration or regulated transendothelial transport.Because sphingosine-1-phosphate (S1P) preserves the endothelial barrier, we investigated in vivo and in vitro, whether S1P and its cognate S1P-receptor 3 (S1P3) regulate the transendothelial transport of lipoproteins. METHODS AND

resultsCompared to apoE-haploinsufficient mice (CTRL), apoE-haploinsufficient mice with additional endothelium-specific knock-in of S1P3 (S1P3-iECKI) showed decreased transport of LDL and Evan's Blue but increased transport of HDL from blood into the peritoneal cave. After 30 weeks of high-fat diet feeding, S1P3-iECKI mice had lower levels of non-HDL-cholesterol and less atherosclerosis than CTRL mice. In vitro stimulation with an S1P3 agonist increased the transport of 125I-HDL but decreased the transport of 125I-LDL through human aortic endothelial cells (HAECs). Conversely, inhibition or knock-down of S1P3 decreased the transport of 125I-HDL but increased the transport of 125I-LDL. Silencing of SCARB1 encoding scavenger receptor B1 (SR-BI) abrogated the stimulation of 125I-HDL transport by the S1P3 agonist. The transendothelial transport of 125I-LDL was decreased by silencing of SCARB1 or ACVLR1 encoding activin-like kinase 1 but not by interference with LDLR. None of the three knock-downs prevented the stimulatory effect of S1P3 inhibition on transendothelial 125I-LDL transport.

conclusionS1P3 regulates the transendothelial transport of HDL and LDL oppositely by SR-BI-dependent and SR-BI-independent mechanisms, respectively. This divergence supports a contention that lipoproteins pass the endothelial barrier by specifically regulated mechanisms rather than passive filtration.

Indexed as

AtherosclerosisEndothelial CellsLipoproteins, HDLLipoproteins, LDLProtein TransportSphingosine-1-Phosphate ReceptorsAnimalsBiological TransportCells, CulturedDisease Models, AnimalHumansLysophospholipidsMiceMice, Inbred C57BLMice, Knockout, ApoEScavenger Receptors, Class BLipoproteins, HDLLipoproteins, LDLLysophospholipidsS1pr3 protein, mouseSCARB1 protein, humanScarb1 protein, mouseScavenger Receptors, Class BSphingosinesphingosine 1-phosphatesphingosine-1-phosphate receptor-3, humanSphingosine-1-Phosphate ReceptorsEndotheliumHDLLDLSphingosine-1-phosphateSR-BI

Identifiers

PMID38109696
PMCPMC11060483
OpenAlexW4389958193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.